Innovation at Prosit Sole
Video Display
-
Our Vision and Mission at Prosit SoleOur Vision and Mission at Prosit Sole -- By CEO of Prosit Sole Dr. Hongyu Liu
-
Why Prosit Sole is one of the most potential orphan drugs biopharma? By Former VP of Novo-Nordisk
Former VP of Novo-Nordisk -
Opinion From Board Director Don D. -- Funder of Rotating Boulder Fund
Founder of Rotating Boulder Fund
Former CEO of KPC Pharmaceuticals Group -
Experts Opinion-- BY Board Director Christian Elling, CEO of Lundbeck Found
CEO of Lundbeck Found Talked About Prosit Sole
Press Release
-
Prosit Sole Biotechnology Initiates First-In-Human Clinical Trial of Novel Interferon Lambda Chimera in US
2021-05-28Baltimore, May26,2021 /--PrositSole Biotechnology,aclinical-stagebiotechcompanydevelopingnovelprotein therapeutics,todayannouncesthatithasinitiatedthefirst-in-human(“ -
PSP001 received Safe-to-proceed Letter by FDA
2021-02-05On 3rd Feb. 2021, FDA issued Safe-to-Proceed letter to investigational new drug application (IND) of PSP001. -
PSP001 (PEGIL29 Chimera) IND submission (FDA)
2021-02-05On 7th Jan 2021 US time (8th Jan 2021, Beijing Time), Prosit Sole Submitted PSP001 (PEGIL29 Chimera) IND to FDA. Appreciated for great effort of Prosit sole's team members. -
Dr. Hongyu Liu, CEO of Prosit Sole Biotechnology (Beijing) attended the Hong Kong Summit of Winner of Nobel Prize and Turing Award at International Center of Innovative Technology, as a leader of inno
2019-08-05Dr. Hongyu Liu, a veteran of the pharmaceutical industry and founder/CEO of an orphan drug company (Prosit Sole Biotechnology (Beijing)), attended the Hong Kong Summit of Winner of Nobel Prize and Turing Award at International Center of Innovative Technol -
Dr. Hongyu Liu, Founder and CEO of Prosit Sole Biotechnology (Beijing), as an invited speaker, attended the 4th Annual Meeting of Founders Club for Innovative Medicines.
2019-08-05Dr. Hongyu Liu, a leader in the discovery and development of innovative orphan drugs in China and globally, conducted a presentation at the 4th Annual Meeting of Founders Club for Innovative Medicines. In his speech, Dr. Liu discussed the market opportuni -
May 2019, Prosit Sole entered into a Partnership with CDDG Group, WA, USA
2019-08-05May 11. 2019, Beijing, PR China and Seattle, WA, USA----Prosit Sole Biotechnology (Beijing, China) and Cascadian Drug Development Group (CDDG, Seattle, WA) signed a formal agreement to form a drug development partnership in advancing PSP001 into the clini
About Prosit Sole
Unmet Medical Needs, Our Social Responsibility
At Prosit Sole, we focus on developing innovative protein therapeutics that address the unmet medical needs for life-threatening rare diseases. Prosit Sole established an advanced Prositsole Protein Optimize Platform (P-POP), a Biologics discovery technology, patented in the US and China, that enables us to discover first-in-class or best-in-class biologics, with excellent efficacy and favorable safety profile. Currently, Prosit Sole has 4 Biologics in various stages of development, the lead product candidates are PEGINF-lchimeric (currently being pursued for IND in the US) and a FGF-18 chimeric (currently in pre-clinical development).
